Repare Therapeutics : Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics' SNIPRx platform for molecular selection of tumors for therapy with RP-3500 - Form 8-K

Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics' SNIPRx platform for molecular selection of tumors for therapy with RP-3500


... | October 8, 2021

Related Keywords

Montreal ,Quebec ,Canada ,Houston ,Texas ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,David Rosen ,Timothy Yap ,Maria Koehler ,Kimberly Minarovich ,Lloydm Segal ,Steve Forte ,Division Of Cancer Medicine ,Company Nasdaq ,Company Virtual Webcast Event ,Md Anderson Cancer Center ,Repare Therapeutics Inc ,Exchange Commission ,Virtual International Conference On Molecular ,Institute For Applied Cancer Science ,Department Of Investigational Cancer Therapeutics ,Company Quarterly ,Repare Therapeutic ,Virtual Webcast Event Today ,Repare Therapeutics ,Treatment Enabled ,International Conference ,Molecular Targets ,Chief Medical Officer ,Chief Executive Officer ,Initial Findings ,Virtual Webcast Event ,Principal Investigator ,Medical Director ,Applied Cancer Science ,Associate Professor ,Investigational Cancer Therapeutics ,Cancer Medicine ,Cancer Center ,Private Securities Litigation Reform Act ,Quarterly Report ,Repare Therapeutics Inc Stock Exchange ,News ,Information ,Press Release ,Nitial ,Presr ,Data ,Rovide ,Linical ,Roof ,F ,Concept ,End ,Validate ,Prepare ,Niprx ,Platform ,Or ,Olecular ,Election ,Rumors ,Therapy ,Ith Rptx Us7602731025 ,